Four Cell & Gene Companies to Know in China
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
Karen was Senior Editor and Business Director with PharmaBoardroom from 2015 to 2021, involved in global biopharma coverage, C-level/executive interviews, special reports & social media. Extensive global editorial and commercial experience with track record of project management and relationship-building at the C-level.
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
While outbreaks of the devastating Ebola virus have – thankfully – generally been highly localized to West Africa, the highly infectious and lethal disease has generated global trepidation due to…
The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for…
The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and AstraZeneca’s joint move to strengthen their manufacturing collaborations, and whether President Duterte’s vaccine diplomacy…
As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM) president & CEO Chip Davis; Carol Lynch,…
With remdesivir practically a household name today as the first therapeutic to be approved for the treatment of COVID-19 patients, Gilead chairman and CEO Daniel O’Day and Gilead vice-president and…
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent…
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth.…
With US still the reigning global champion in biotech innovation, the dynamic and vibrant biopharma ecosystem in the world’s largest healthcare market continues to churn out ground-breaking innovations with companies…
The latest from the fight against COVID-19 in Latin America, including J&J’s vaccine trials, issues surrounding Chinese-made diagnostic tests, Colombia’s vaccine manufacturing capacity, and potential compulsory licensing in Brazil. …
During the fourth International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) COVID-19 media briefing, one thematic dominated: collaboration. With Eli Lilly chairman and CEO David Ricks, also president of IFPMA;…
See our Cookie Privacy Policy Here
